The goal of this review is to highlight the main players in the regulation of CML LSCs and then to focus on DYRK2, which has been identified as a novel molecular target for the development of LSC-specific therapy. This evidence concerns the gene DYRK2 and chronic myelogenous leukemia, BCR-ABL1 positive.